home / stock / abbv / abbv articles

ABBV Articles, AbbVie Inc. - From 04/26/24

Stock Information
Company Name: AbbVie Inc.
Stock Symbol: ABBV
Market: NYSE
Website: abbvieinvestor.com
Menu
ABBV ABBV Quote ABBV Short ABBV News ABBV Articles ABBV Message Board
Get ABBV Alerts

News, Short Squeeze, Breakout and More Instantly...
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook | Benzinga

Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net...
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet | Benzinga

Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants&nb...

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study | Benzinga

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Pha...

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week | Benzinga

As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study | Benzinga

On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...

Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions | Benzinga

On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE:ABB...

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today | Benzinga

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. C...
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades | Benzinga

Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says | Benzinga

Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulation...

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape | Benzinga

FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a pot...
Previous 10 Next 10